Please check your internet connection and try again.
## Ecospirin (Aspirin, Enteric-Coated)
### Overview
Ecospirin is an enteric-coated formulation of aspirin, a nonsteroidal anti-inflammatory drug (NSAID) with analgesic, antipyretic, and antiplatelet properties. The enteric coating is designed to delay drug release until it reaches the small intestine, potentially reducing gastric irritation.
### Primary Indications
* **Cardiovascular protection:** Prevention of myocardial infarction and stroke in patients with established cardiovascular disease or risk factors.
* **Analgesia and antipyresis:** Relief of mild to moderate pain and fever.
### Adult Dosing
* **Cardiovascular protection:** Typically 75 mg to 100 mg once daily. Higher doses (e.g., 325 mg) may be used initially in some acute settings, but maintenance is usually at lower doses.
* **Analgesia and antipyresis:** 325 mg to 650 mg every 4 to 6 hours as needed. Maximum daily dose generally not to exceed 4000 mg.
### Pediatric Dosing
* **Analgesia and antipyresis:** Generally **avoided** in children and adolescents under 19 years of age due to the risk of Reye's syndrome, particularly during viral illnesses. If absolutely necessary, dosing should be based on specific guidelines and under strict medical supervision. **No established safe pediatric dose for routine use.**
### Dose Adjustments
* **Renal impairment:** Use with caution. Dose reduction may be necessary in severe renal impairment.
* **Hepatic impairment:** Use with caution. Monitor liver function.
### Contraindications
* Hypersensitivity to aspirin, other salicylates, or NSAIDs.
* History of aspirin-induced asthma, urticaria, or other allergic-type reactions.
* Active peptic ulceration or recent gastrointestinal bleeding.
* Children and adolescents with viral infections (risk of Reye's syndrome).
* Concomitant use with methotrexate at doses of 15 mg/week or higher.
* Hemophilia, other bleeding disorders.
### Adverse Effects
* **Gastrointestinal:** Dyspepsia, nausea, vomiting, abdominal pain, bleeding, ulceration.
* **Hematologic:** Increased bleeding risk, bruising.
* **Hypersensitivity:** Bronchospasm, rash, urticaria.
* **Other:** Tinnitus (especially at higher doses), dizziness.
### Key Drug Interactions
* **Anticoagulants (e.g., warfarin, heparin, DOACs):** Increased risk of bleeding.
* **Other NSAIDs and COX-2 inhibitors:** Increased risk of gastrointestinal bleeding and reduced antiplatelet effect of aspirin.
* **Corticosteroids:** Increased risk of gastrointestinal ulceration and bleeding.
* **Alcohol:** Increased risk of gastrointestinal irritation and bleeding.
* **Methotrexate:** Increased risk of methotrexate toxicity.
* **Antihypertensives (e.g., ACE inhibitors, ARBs, diuretics):** May reduce their efficacy and increase risk of renal dysfunction.
* **Uricosuric agents (e.g., probenecid):** Reduced efficacy.
### Monitoring
* Signs and symptoms of gastrointestinal bleeding (melena, hematemesis, abdominal pain).
* Signs and symptoms of increased bleeding (bruising, epistaxis).
* Renal function and electrolytes, especially in patients with pre-existing renal disease or those taking concomitant nephrotoxic agents.
* Liver function tests, particularly with chronic use or in patients with hepatic impairment.
* Tinnitus may indicate toxicity.
### Clinical Pearls
* The enteric coating helps to minimize gastric irritation but does not eliminate the risk of gastrointestinal bleeding, especially with chronic use or in high-risk patients.
* For cardiovascular protection, low-dose aspirin is generally preferred.
* Aspirin should be discontinued at least 5-7 days prior to elective surgery to reduce bleeding risk.
* Enteric-coated aspirin should not be crushed or chewed.
* Reye's syndrome is a serious, potentially fatal illness associated with aspirin use in children and adolescents during viral infections.
***
*Disclaimer: This information is intended for clinical professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions.*
